The incremental value of aspartate aminotransferase/alanine aminotransferase ratio combined with CURB-65 in predicting treatment outcomes in hospitalized adult community-acquired pneumonia patients with type 2 diabetes mellitus

Table 3 Independent variables for treatment outcome in CAP patients with T2DM

Variables	Comparison groups	Odds ratio	95% CI	p value
CURB-65 (points)	2 vs. 0–1	6.349	2.194–18.374	0.001
	3–5 vs. 0–1	10.037	3.051–33.015	< 0.001
PLR	≥ 191.821 vs. < 191.821	4.541	1.857–11.107	0.001
AST/ALT	≥ 1.625 vs. < 1.625	3.672	1.455–9.268	0.006
WBC (× 10⁹/L)	≥ 10.7 vs. < 10.7	3.270	1.341–7.976	0.009

Adjusted for gender, age, comorbidities, and other biomarkers
CAP community-acquired pneumonia, T2DM type 2 diabetes mellitus, PLR platelet-lymphocyte ratio, AST/ALT aspartate aminotransferase/alanine aminotransferase ratio, WBC white blood cell

ISSN: 1471-2466